Findings by RXi Pharmaceuticals Corp. of Worcester on a treatment for Lou Gehrig’s Disease have been published in the April edition of a peer-reviewed science journal.
The Journal of Biological Chemistry selected the paper as a “paper of the week,” meaning it ranks in significance in the top 1 percent of papers they review.
The research, performed by UMass Medical School researchers and RXi scientific advisors, used animal models to demonstrate the use of RNA interference to inhibit a gene that can cause ALS.
In January, RXi announced that it had entered into an exclusive licensing agreement with the medical school for the technology described in the paper.
